HYDRHA: Hydrogels of hyaluronic acid. New biomedical approaches in cancer, neurodegenerative diseases, and tissue engineering

Grieco, Maddalena; Ursini, Ornella; Palamà, Ilaria Elena; Gigli, Giuseppe; Moroni, Lorenzo; Cortese, Barbara

doi:10.1016/j.mtbio.2022.100453

Cited by 13 publications

(8 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medication thickening, the formation of conjugates when HA and its derivatives are utilized as carriers, sustained release, and improved drug targeting have all been demonstrated [ 146 ]. Therefore, this polymer may be a promising option for treating neurodegenerative diseases and brain tumors [ 147 ].…”

Section: Coating Polymersmentioning

confidence: 99%

Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform

et al. 2023

View full text Add to dashboard Cite

The blood–brain barrier (BBB) serves as a protective barrier for the central nervous system (CNS) against drugs that enter the bloodstream. The BBB is a key clinical barrier in the treatment of CNS illnesses because it restricts drug entry into the brain. To bypass this barrier and release relevant drugs into the brain matrix, nanotechnology-based delivery systems have been developed. Given the unstable nature of NPs, an appropriate amount of a biocompatible polymer coating on NPs is thought to have a key role in reducing cellular cytotoxicity while also boosting stability. Human serum albumin (HSA), poly (lactic-co-glycolic acid) (PLGA), Polylactide (PLA), poly (alkyl cyanoacrylate) (PACA), gelatin, and chitosan are only a few of the significant polymers mentioned. In this review article, we categorized polymer-coated nanoparticles from basic to complex drug delivery systems and discussed their application as novel drug carriers to the brain.

show abstract

Section: Coating Polymersmentioning

confidence: 99%

Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Regarding their use in neurodegenerative diseases, recent reviews have summarized the main outcome of different nano‐DDS in AD and PD treatment (Akhtar et al, 2021). The key aspects for the use of inorganic nanoparticles (Nguyen et al, 2021), dendrimers (Xu et al, 2014), polymeric nanoparticles (Zhang et al, 2021)—different form PLGA ones—as well as hydrogels (Fernandez‐Serra et al, 2020; Grieco et al, 2022) or cell‐based systems (Nowak et al, 2020) have been deeply revised before.…”

Section: Synthetic Drug Delivery Systems (Dds) To Target the Cns: Pol...mentioning

confidence: 99%

Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease

Hernando

Santos‐Vizcaíno

Igartua

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD) are an accelerating global health problem as life expectancy rises worldwide. Despite their significant burden in public health systems to date, the existing treatments only manage the symptoms without slowing down disease progression. Thus, the ongoing neurodegenerative process remains untreated. Moreover, the stronghold of the brain—the blood–brain barrier (BBB)—prevents drug penetrance and dwindles effective treatments. In the last years, nanotechnology‐based drug delivery systems (DDS) have become a promising approach to target and treat these disorders related to the central nervous system (CNS). PLGA based nanoparticles (NPs) were the first employed DDS for effective drug delivery. However, the poor drug loading capacity and localized immunogenicity prompted the scientific community to move to another DDS such as lipid‐based NPs. Despite the lipid NPs' safety and effectiveness, their off‐target accumulation together with the denominated CARPA (complement activation‐related pseudo allergy) reaction has limited their complete clinical translation. Recently, biological NPs naturally secreted by cells, termed as extracellular vesicles (EVs) have emerged as promising more complex biocompatible DDS. In addition, EVs act as dual players in NDs treatment, as a “cell free” therapy themselves, as well as new biological NPs with numerous characteristics that qualify them as promising carriers over synthetic DDS. The present review aims to display advantages, drawbacks, current limitations and future prospective of the previously cited synthetic and biological DDS to enter the brain and treat one of 21st century most challenging diseases, NDs.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

show abstract

“…By harnessing the synergistic effects of HA with other therapeutic agents, it is possible to enhance its regenerative, anti-inflammatory, and analgesic properties, opening up new avenues for personalized medicine and tissue engineering approaches [ 161 , 162 , 163 ]. Further research is warranted to elucidate the precise molecular mechanisms and evaluate the efficacy of targeted interventions in clinical settings with respect to long-term safety and cost-effectiveness of combination therapies involving HA.…”

Section: Therapeutic Approachesmentioning

confidence: 99%

Hyaluronic Acid in Rheumatology

Sprott,

Fleck

2023

Pharmaceutics

View full text Add to dashboard Cite

Hyaluronic acid (HA), also known as hyaluronan, is an anionic glycosaminoglycan widely distributed throughout various tissues of the human body. It stands out from other glycosaminoglycans as it lacks sulfation and can attain considerable size: the average human synovial HA molecule weighs about 7 million Dalton (Da), equivalent to roughly 20,000 disaccharide monomers; although some sources report a lower range of 3–4 million Da. In recent years, HA has garnered significant attention in the field of rheumatology due to its involvement in joint lubrication, cartilage maintenance, and modulation of inflammatory and/or immune responses. This review aims to provide a comprehensive overview of HA’s involvement in rheumatology, covering its physiology, pharmacology, therapeutic applications, and potential future directions for enhancing patient outcomes. Nevertheless, the use of HA therapy in rheumatology remains controversial with conflicting evidence regarding its efficacy and safety. In conclusion, HA represents a promising therapeutic option to improve joint function and alleviate inflammation and pain.

show abstract

HYDRHA: Hydrogels of hyaluronic acid. New biomedical approaches in cancer, neurodegenerative diseases, and tissue engineering

Cited by 13 publications

References 200 publications

Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform

Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform

Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease

Hyaluronic Acid in Rheumatology

Contact Info

Product

Resources

About